All In Biotech

NDA 018225 · Validus Pharms

Bumex

Bumetanide · Oral · Loop Diuretic

Novel

Last checked: Nov 20, 2026Latest source record: Jan 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1983

Feb 28, 1983

Approved uses

2

Original approval plus efficacy supplements

Registered trials

45

9 Phase 3, 9 recruiting

FAERS reports

26,832

20,610 serious, 4,181 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient's needs (see DOSAGE AND ADMINISTRATION ) .

What it is approved for

From the label in effect Dec 17, 2025.

INDICATIONS AND USAGE Bumetanide tablets are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 14, 1985 Supplement 2 · Efficacy
  • Feb 28, 1983 Original approval · Type 1 - New Molecular Entity
3 products under this application
  • BUMEX · BUMETANIDE 0.5MG · TABLET, ORAL · Prescription · TE AB
  • BUMEX · BUMETANIDE 2MG · TABLET, ORAL · Prescription · TE AB
  • BUMEX · BUMETANIDE 1MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Bumetanide" as an intervention, any sponsor and status, largest first.

All 45 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea2,720
  • fatigue1,780
  • death1,731
  • acute kidney injury1,711
  • diarrhoea1,628
  • nausea1,585
  • dizziness1,330
  • headache1,301
  • pneumonia1,152
  • renal failure1,142
  • asthenia1,101
  • hypotension1,081

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004298
2005377
2006366
2007315
2008334
2009411
2010550
2011677
2012719
2013749
2014992
20151,302
20161,653
20171,658
20181,859
20191,944
20201,960
20211,443
20221,357
20231,728
20242,157
20252,268
20261,714

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 179 on PubMed

Sponsor: Validus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.